IP83-04: Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan

IP83-04: Increased risk of interstitial lung disease with enfortumab vedotin plus pembrolizumab compared with sequential enfortumab vedotin in metastatic urothelial carcinoma: A multicenter retrospective study in Japan

Monday, May 18, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147A
Abstract

Log in

See all the content and easy-to-use features by logging in or registering!